ArticleAdvances in therapy2022

Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer.

Jesse A Sussell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.